8 September 2015 - A powerful new class of cholesterol-lowering injections should cost about 85% less than what is charged per patient for the treatments in the U.S., according to a nonprofit research group flush with new philanthropic funding to target high prescription-drug costs.

The Institute for Clinical and Economic Review in Boston issued a report Tuesday saying the new drugs—Praluent from Sanofi SA and Regeneron Pharmaceuticals, and Amgen Inc.’s Repatha—would be cost-effective if priced at about $2,180 a year per patient.

Amgen priced Repatha at about $14,100 a year, and Praluent costs about $14,600.

A Sanofi spokeswoman said Sanofi and Regeneron are reviewing the ICER report and would respond at a later time.

For more details, go to: http://www.wsj.com/articles/new-class-of-cholesterol-drugs-should-cost-much-less-report-says-1441752760?tesla=y